DeepMed Research

ASAN FOUNDATION

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1989-06-23

Employees: 501

Market Cap: -

Website: https://ails.amc.seoul.kr

Clinical Trials

Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer

Phase 1

Completed

Conditions: Stomach Cancer

Interventions: Drug: Docetaxel, Capecitabine and Oxaliplatin

First Posted Date: 2007-03-12

Last Posted Date: 2020-01-18

Lead Sponsor: Asan Medical Center

Target Recruit Count: 22

Registration Number: NCT00446290

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Genetic Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP)

Completed

Conditions: Pancreatitis

First Posted Date: 2007-03-07

Last Posted Date: 2007-06-26

Lead Sponsor: Asan Medical Center

Target Recruit Count: 40

Registration Number: NCT00444444

Locations: 🇰🇷
Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of

Study of XELOX With Cetuximab in Advanced Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine, Oxaliplatin, Cetuximab

First Posted Date: 2006-11-10

Last Posted Date: 2020-01-07

Lead Sponsor: Asan Medical Center

Target Recruit Count: 44

Registration Number: NCT00398398

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Korea Cancer Center Hospital, Seoul, Korea, Republic of

Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

Not Applicable

Conditions: Polypoidal Choroidal Vasculopathy

First Posted Date: 2006-10-04

Last Posted Date: 2006-10-04

Lead Sponsor: Asan Medical Center

Target Recruit Count: 20

Registration Number: NCT00383812

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Phase 1

Completed

Conditions: Lymphoma, Large-Cell, Diffuse
Lymphoma, B-Cell

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Drug: Lenograstim

First Posted Date: 2006-09-22

Last Posted Date: 2013-03-15

Lead Sponsor: Asan Medical Center

Target Recruit Count: 49

Registration Number: NCT00379574

Locations: 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
🇰🇷
Asan Medical Cener, Seoul, Korea, Republic of

Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Bevacizumab

First Posted Date: 2006-09-19

Last Posted Date: 2013-01-23

Lead Sponsor: Asan Medical Center

Target Recruit Count: 49

Registration Number: NCT00378066

Locations: 🇰🇷
Yonsei University Hospital, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 3 locations

Gemcitabine for Marginal Zone Lymphoma

Phase 2

Terminated

Conditions: Non-Hodgkin's Lymphoma
Marginal Zone Lymphoma

Interventions: Drug: gemcitabine

First Posted Date: 2006-06-15

Last Posted Date: 2016-02-17

Lead Sponsor: Asan Medical Center

Target Recruit Count: 43

Registration Number: NCT00337259

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Oxaliplatin

First Posted Date: 2006-06-14

Last Posted Date: 2018-06-26

Lead Sponsor: Asan Medical Center

Target Recruit Count: 27

Registration Number: NCT00336583

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Zevalin-BuCyE

First Posted Date: 2006-06-14

Last Posted Date: 2016-02-17

Lead Sponsor: Asan Medical Center

Target Recruit Count: 19

Registration Number: NCT00336843

Locations: 🇰🇷
Asan Medical Center, Departement of Internal Medicine, Division of Oncology, Seoul, Korea, Republic of

Efficacy and Safety of Intravitreal Triamcinolone Acetonide in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage

Not Applicable

Conditions: Post Vitrectomy State
Recurrent Diabetic Vitreous Hemorrhage

First Posted Date: 2006-03-08

Last Posted Date: 2007-06-13

Lead Sponsor: Asan Medical Center

Target Recruit Count: 30

Registration Number: NCT00300014

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy